Cover Image
市場調查報告書

關注市場分析:遺傳性血管水腫 (HAE)

Market Spotlight: Hereditary Angioedema (HAE)

出版商 Datamonitor Healthcare 商品編碼 594576
出版日期 內容資訊 英文 34 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:遺傳性血管水腫 (HAE) Market Spotlight: Hereditary Angioedema (HAE)
出版日期: 2017年10月27日 內容資訊: 英文 34 Pages
簡介

本報告提供遺傳性血管水腫 (HAE)的治療藥市場相關分析,疾病概要和患者數的變化、預測,目前的主要的調查治療方法,現在與開發中臨床實驗的進展與上市計劃,主要的治療藥的市場趨勢預測 (今後10年份),資本交易的動向等。

分析的要點

疾病的背景情況

  • 亞型

治療方法

  • C1-INH濃縮物
  • 血漿來源C1-INH (PdC1-INH)
  • 基因改造型C1-INH (RhC1-INH)
  • 激肽釋放酶抑制劑
  • 緩激肽受體拮抗劑

流行病學

已上市醫藥品

  • 各國的認證情形

開發平台上的醫藥品

將產生的主要事件

授權合約、資產收購交易

  • Pharming取回Ruconest相關的權利,以擴大影響力

母體專利

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各相位
  • Shire:新版本的Cinryze,HAE市場上的CSL 探尋跟Behring的新競爭方法
  • Shire的CEO的講話:「SHP643開發成果,導致Dyax的收購、M&A策略」
  • CSL Behring:容易給藥的HAE預防藥,接近市場

相關分析

  • 處方藥的資訊

附錄

目錄
Product Code: DMKC0180962

This Market Spotlight report covers the Hereditary Angioedema market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

  • Datamonitor Healthcare estimates that in 2016 the estimated number of cases ranged from 49,600-743 300. The approved drugs in the hereditary angioedema space target complement proteins, androgen receptors, follicle-stimulating hormones, gonadotropin-releasing hormones, progesterone receptors, bradykinin B2 receptors, and the kinin-kallikrein system. These are commonly administered via the intravenous or subcutaneous routes, with one product being available in oral formulation.
  • Therapies in mid-to-late-stage development for hereditary angioedema focus on targets such as the kinin-kallikrein system and complement proteins. These drugs are administered via the subcutaneous and oral routes.
  • High impact upcoming events for drugs in the hereditary angioedema space include topline Phase III trial results and loss of product exclusivity.
  • Licensing and asset acquisition activity involving hereditary angioedema drugs has been weak during 201217, with only five deals over this time period. The $125m agreement between Pharming and Valeant for the acquisition of all the North American rights to Ruconest, was the largest deal during 2012-17.
  • Firzyr's US parent product patent is set to expire in 2019, which will open the door to generic entry. Cinryze's sales ranked highest among drugs available for hereditary angioedema during 2012-16, and revenues are expected to remain high until 2021.
  • The clinical trials distribution across Phase I-IV indicates that the majority of trials for hereditary angioedema have been in late phases of development, with 52.6% of trials in Phase III-IV, and 47.4% in Phase I-II.
  • The US has a substantial lead in the number of hereditary angioedema clinical trials globally. The UK leads the major EU markets, while Israel has the top spot in Asia.
  • Clinical trial activity in the hereditary angioedema space is dominated by completed trials. Shire has the highest number of completed trials for hereditary angioedema.
  • Shire leads industry sponsors with the highest number of clinical trials for hereditary angioedema.

TABLE OF CONTENTS

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • C1-INH concentrates
  • Plasma-derived C1-INH (PdC1-INH)
  • Recombinant C1-INH (RhC1-INH)
  • Kallikrein inhibitor
  • Bradykinin receptor antagonist

EPIDEMIOLOGY

MARKETED DRUGS

  • Approvals by country

PIPELINE DRUGS

KEY UPCOMING EVENTS

LICENSING AND ASSET ACQUISITION DEALS

  • Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze
  • Shire CEO Says SHP643 Results Vindicate Dyax Buy, M&A Strategy
  • CSL Behring Nears Market With Easier-To-Administer HAE Prophylactic

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of hereditary angioedema, 2016-25
  • Figure 2: Pipeline drugs for hereditary angioedema in the US
  • Figure 3: Pipeline drugs for hereditary angioedema, by company
  • Figure 4: Pipeline drugs for hereditary angioedema, by drug type
  • Figure 5: Pipeline drugs for hereditary angioedema, by classifications
  • Figure 6: Key upcoming events in hereditary angioedema
  • Figure 7: Parent patents in hereditary angioedema
  • Figure 8: Clinical trials in hereditary angioedema
  • Figure 9: Top 10 drugs for clinical trials in hereditary angioedema
  • Figure 10: Top 10 companies for clinical trials in hereditary angioedema
  • Figure 11: Trial locations in hereditary angioedema
  • Figure 12: Hereditary angioedema trials sponsors, by status
  • Figure 13: Hereditary angioedema trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of hereditary angioedema, 2016-25
  • Table 2: Marketed drugs for hereditary angioedema
  • Table 3: Approvals by country for hereditary angioedema
  • Table 4: Pipeline drugs for hereditary angioedema in the US
  • Table 5: Historical global sales, by drug ($m), 2012-16
  • Table 6: Forecasted global sales, by drug ($m), 2017-22
Back to Top